阿托莫西汀联合奥昔布宁大幅降低阻塞性睡眠呼吸暂停严重度
一项随机、安慰剂对照、双盲交叉试验纳入20例OSA患者,比较睡前单晚服用80 mg阿托莫西汀+5 mg奥昔布宁与安慰剂的效应。联合用药使AHI降低63%(34-86%),从28.5降至7.5事件/h(P<0.001),颏舌肌反应性增大约三倍。两药单用均未降低AHI。
要点
- 阿托莫西汀80 mg联合奥昔布宁5 mg单晚即可使AHI降低63%。
- 基线AHI>10的15例患者中,AHI降低74%且全部降幅≥50%。
- 两药单用无效,提示联合用药是必要条件。
核心结论
- 睡前口服去甲肾上腺素能联合抗毒蕈碱药物单晚即可大幅降低OSA严重度。
- 联合用药为OSA药物治疗提供了新可能。
研究设计与样本
- 随机、安慰剂对照、双盲交叉试验,共20人完成。
- 比较睡前1晚80 mg阿托莫西汀+5 mg奥昔布宁与安慰剂。
- 通过实验室多导睡眠监测测AHI和颏舌肌对负压食道压力波动的反应性。
- 9例亚组另测两药分别单用时的AHI。
主要发现
- 受试者中位年龄53(46-58)岁,BMI 34.8(30.0-40.2)kg/m2。
- 联合用药使AHI降低63%(34-86%),从28.5(10.9-51.6)降至7.5(2.4-18.6)事件/h(P<0.001)。
- 安慰剂时AHI>10事件/h的15/20例患者,AHI降低74%(62-88%)(P<0.001),全部15例降幅≥50%。
- 颏舌肌反应性从安慰剂时2.2(1.1-4.7)%/cm H2O增至6.3(3.0-18.3)%/cm H2O(P<0.001),约三倍。
- 阿托莫西汀或奥昔布宁单用均未降低AHI。
临床怎么用
- 提示阿托莫西汀联合奥昔布宁可作为OSA药物治疗的研究方向。
- 目前证据仅限单晚用药,尚不能直接用于临床处方。
局限性
- 样本量小(20例完成,亚组仅9例)。
- 仅评估单晚用药效果。
- 未报告长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: There is currently no effective pharmacological treatment for obstructive sleep apnea (OSA). Recent investigations indicate that drugs with noradrenergic and antimuscarinic effects improve genioglossus muscle activity and upper airway patency during sleep. Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in people with OSA. Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy) to placebo administered before sleep. The AHI and genioglossus muscle responsiveness to negative esophageal pressure swings were measured via in-laboratory polysomnography. In a subgroup of nine patients, the AHI was also measured when the drugs were administered separately. Measurements and Main Results: The participants' median (interquartile range) age was 53 (46-58) years and body mass index was 34.8 (30.0-40.2) kg/m2. ato-oxy lowered AHI by 63% (34-86%), from 28.5 (10.9-51.6) events/h to 7.5 (2.4-18.6) events/h (P < 0.001). Of the 15/20 patients with OSA on placebo (AHI > 10 events/hr), AHI was lowered by 74% (62-88%) (P < 0.001) and all 15 patients exhibited a ≥50% reduction. Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1-4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato-oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately. Conclusions: A combination of noradrenergic and antimuscarinic agents administered orally before bedtime on 1 night greatly reduced OSA severity. These findings open new possibilities for the pharmacologic treatment of OSA. Clinical trial registered with www.clinicaltrials.gov (NCT02908529).
引用
- Taranto-Montemurro L, Messineo L, Sands SA, et al. The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial. Am J Respir Crit Care Med. 2019. PMID: 30395486. doi:10.1164/rccm.201808-1493OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。